Desunin® 800IU is indicated for the prevention and treatment of vitamin D deficiency in adults and adolescents1.
Desunin® 4000IU is licensed for the treatment of vitamin D deficiency, defined as <25nmol/l2. In addition to specific osteoporosis treatment of patients who are at risk of vitamin D deficiency, supplemental calcium should be considered1,2.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Meda's Medical Information line on 01748 828810.
1. Summary of Product Characteristics Desunin 800IU, Meda Pharmaceuticals, June 2014
2. Summary of Product Characteristics Desunin 4000IU, Meda Pharmaceuticals, June 2016
3. Pearce S, Cheetham T. Diagnosis and management of vitamin D deficiency. BMJ, 2010; 340:b5664.